BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 35436142)

  • 1. Comparison of preventive effects of combined furosemide and mannitol versus single diuretics, furosemide or mannitol, on cisplatin-induced nephrotoxicity.
    Takagi A; Miyoshi T; Hayashi T; Koizumi H; Tsumagari K; Yokota C; Nakano T; Matsuo K; Egawa T
    Sci Rep; 2024 May; 14(1):10511. PubMed ID: 38714773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: which dose is more suitable?
    Ilhan Y; Onder AH; Ozbay MF; Karakaya G; Sezgin Goksu S; Ozturk B; Coskun HS
    Eur Rev Med Pharmacol Sci; 2024 May; 28(9):3403-3413. PubMed ID: 38766796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Magnesium supplementation therapy to prevent cisplatin-induced acute nephrotoxicity in pediatric cancer: a randomized phase-2 trial.
    Matsui M; Makimoto A; Chin M; Koh K; Tomotsune M; Kaneko T; Morikawa Y; Hamada R; Yuza Y
    Int J Clin Oncol; 2024 May; 29(5):629-637. PubMed ID: 38564107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term cisplatin nephrotoxicity after childhood cancer: a systematic review and meta-analysis.
    Schofield J; Harcus M; Pizer B; Jorgensen A; McWilliam S
    Pediatr Nephrol; 2024 Mar; 39(3):699-710. PubMed ID: 37726572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of Dextrose Hypotonic vs Saline Hydration on Methotrexate-Induced Nephrotoxicity in Male and Female Rats.
    Hasanpour Z; Choopani S; Ashrafi F; Talebi A; Nematbaksh M
    Adv Biomed Res; 2024; 13():14. PubMed ID: 38525397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic Variations and Cisplatin Nephrotoxicity: A Systematic Review.
    Zazuli Z; Vijverberg S; Slob E; Liu G; Carleton B; Veltman J; Baas P; Masereeuw R; Maitland-van der Zee AH
    Front Pharmacol; 2018; 9():1111. PubMed ID: 30319427
    [No Abstract]   [Full Text] [Related]  

  • 7. Mannitol versus furosemide in patients with thoracic malignancies who received cisplatin-based chemotherapy using short hydration: A randomized phase II trial.
    Murakami E; Akamatsu H; Teraoka S; Takakura T; Takase E; Tanaka M; Kaki T; Harutani Y; Furuta K; Sugimoto T; Shibaki R; Fujimoto D; Hayata A; Ozawa Y; Nakanishi M; Koh Y; Shimokawa T; Yamamoto N
    Cancer Med; 2024 Feb; 13(4):e6839. PubMed ID: 38457231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccarin alleviates cisplatin-induced acute kidney injury via decreasing NOX4-derived ROS.
    Wu T; Ma W; Lu W; Huangshen Z; Chen S; Yang Q; Li C; Li Z; Li N; Feng X; Li L; Miao Y; Wang J; Liu X; Cai Y; He Y; He X; Li J; Zhao R; Wen J
    Heliyon; 2023 Nov; 9(11):e21231. PubMed ID: 38027630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydration Methods for Cisplatin Containing Chemotherapy: A Systematic Review.
    Sikking C; Niggebrugge-Mentink KL; van der Sman ASE; Smit RHP; Bouman-Wammes EW; Beex-Oosterhuis MM; van Kesteren C
    Oncologist; 2024 Feb; 29(2):e173-e186. PubMed ID: 37995306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin in Liver Cancer Therapy.
    Hamaya S; Oura K; Morishita A; Masaki T
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crystalloid Solutions in Hospital: A Review of Existing Literature.
    Panchal V; Sivasubramanian BP; Samala Venkata V
    Cureus; 2023 May; 15(5):e39411. PubMed ID: 37362468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pro-Inflammatory Signalling PRRopels Cisplatin-Induced Toxicity.
    Domingo IK; Latif A; Bhavsar AP
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effect of Intravenous Mannitol Combined With Normal Saline in Preventing Cisplatin-Induced Nephrotoxicity: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Sainamthip P; Saichaemchan S; Satirapoj B; Prasongsook N
    JCO Glob Oncol; 2022 Mar; 8():e2100275. PubMed ID: 35436142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy.
    McKibbin T; Cheng LL; Kim S; Steuer CE; Owonikoko TK; Khuri FR; Shin DM; Saba NF
    Support Care Cancer; 2016 Apr; 24(4):1789-93. PubMed ID: 26446698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the effect of acetazolamide versus mannitol on cisplatin-induced nephrotoxicity, a pilot study.
    El Hamamsy M; Kamal N; Bazan NS; El Haddad M
    Int J Clin Pharm; 2018 Dec; 40(6):1539-1547. PubMed ID: 30167970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial.
    Santoso JT; Lucci JA; Coleman RL; Schafer I; Hannigan EV
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):13-8. PubMed ID: 12719883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ability of mannitol to decrease cisplatin-induced nephrotoxicity in children: real or not?
    Ruggiero A; Rizzo D; Trombatore G; Maurizi P; Riccardi R
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):19-26. PubMed ID: 26589789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of mannitol as a nephroprotectant in patients receiving cisplatin therapy.
    Morgan KP; Buie LW; Savage SW
    Ann Pharmacother; 2012 Feb; 46(2):276-81. PubMed ID: 22298599
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.